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Abstract 
Background: Contemporary potentially malignant disorder management is 
based upon provisional histological diagnosis followed by interventional 
surgery to excise or ablate ‘high risk’ mucosal lesions. Although the majority 
of patients achieve disease free status post-treatment, others develop further 
or persistent disease unresponsive to intervention.   
Methods: A detailed, retrospective clinico-pathological review of treatment 
resistant potentially malignant lesions, from a 590 patient cohort treated by 
CO2 laser surgery and followed for a mean of 7.3 years, was undertaken. 
Clinical outcome was determined at study census date (31 December 2014).   
Results: A total of 87 patients (15%) exhibited PMD disease resistant to 
treatment: 34 (6%) became disease free following further treatment, whilst 53 
(9%) had persistent disease despite intervention. Disease free patients were 
younger, changed lesion appearance from erythroleukoplakia to leukoplakia 
(p=0.004), developed further lesions at new sites, demonstrated reduction in 
dysplasia severity with time, and required multiple treatments to achieve 
disease free status (p=0.0005). In contrast, persistent disease patients were 
older, male, often presented with proliferative verrucous leukoplakia on 
gingival and alveolar sites, displayed less severe dysplasia initially and 
underwent laser ablation rather than excision (p=0.027).  
Conclusion: Despite clinico-pathological profiling of treatment resistant 
patients, the precise inter-relationship between the inherent nature of 
potentially malignant disease and the external influence of treatment 
intervention remains obscure.  
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Introduction 
Oral potentially malignant disorders (PMD), most frequently leukoplakia but 
also erythroplakia, erythroleukoplakia and proliferative verrucous leukoplakia 
(PVL), are distinct, clinically recognisable mucosal lesions known to precede 
invasive squamous cell carcinoma (SCC) development. Understanding of 
their natural history and risk of progression remains elusive in contemporary 
clinical practice1,2. PMDs are characterised by variable epithelial 
disorganisation and dysmaturation changes, identified microscopically as 
dysplasia, and subjectively graded for severity1,2. Systematic review has 
estimated an overall 12% risk of SCC development over a mean 
transformation time of 4.3 years, but with increased risk for 
erythroleukoplakia, lesions exhibiting more severe dysplasia and origin on 
ventro-lateral tongue and floor of mouth sites3-5.  
Whilst long-term observational studies of PMD patients have been advised to 
increase knowledge and identify reliable clinico-pathological predictors of 
disease outcome6,7, PMD management is based upon incision biopsy for 
provisional histological assessment followed by surgical excision to provide 
definitive diagnoses and treatment of lesions deemed ‘high-risk’4,8.  
It has been suggested, however, that PMD natural history may be 
independent of treatment intervention, and that a subgroup of lesions may be 
resistant to treatment and pre-destined for cancer development, although this 
seems a distinctly negative perspective9. 
We have previously documented clinical outcomes in a 590 PMD patient 
cohort undergoing standardised interventional CO2 laser treatment, primarily 
excision surgery but also utilising ablation techniques for small or less 
dysplastic lesions on gingival and alveolar sites6. Post-treatment, 404 
patients from this cohort (68.4%) were found to be disease free, 99 (16.8%) 
exhibited unexpected or subsequently developing SCC, whilst 87 were 
resistant to treatment developing further or persistent PMD disease during 
the mean 7.3 years follow-up period4,5.  
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The specific purpose of this paper, therefore, was to review in depth the 
clinico-pathological features of these 87 ‘treatment resistant’ PMDs, to 
document each individual patient ‘journey’ and try to improve knowledge of 
the natural history of PMD disease and thereby identify features potentially 
predictive of poor outcome post-treatment. 
 
Method 
Caldicott Approval from Newcastle University / Newcastle upon Tyne 
Hospitals NHS Foundation Trust facilitated anonymized, retrospective data 
collection from medical records, operating books and original pathology 
reports from PMD patients treated by laser in Maxillofacial Surgery between 
August 1996 and December 2014. Inclusion criteria required new patients 
who presented with single-site disease resistant to initial treatment 
intervention. Recorded demographic and clinico-pathological data included: 
patient age and sex, appearance and site of presenting PMD, histopathology 
diagnoses, date, number and type of treatment interventions (laser excision 
or ablation), appearance and site of further or persistent PMD, and clinical 
outcome at the study census date (31 December 2014).  
All biopsies and CO2 laser surgeries were carried out by the first author 
(PJT), or colleagues working under direct supervision, to established 
guidelines and within 6 to 12 weeks of initial presentation to prevent disease 
progression4. Formalin-fixed tissue specimens were assessed via 
standardized histopathology examination by oral pathologists at the Royal 
Victoria Infirmary using agreed diagnostic criteria, peer review and 
consensus grading4. The World Health Organization (WHO) system was 
used and dysplasia classified as mild, moderate and severe or carcinoma-in-
situ (CiS). Diagnoses of hyperkeratosis (HK), lichenoid inflammation (LI), 
PVL and chronic hyperplastic candidosis (CHC) were made as appropriate.  
Clinical outcomes were defined as: disease free or persistent disease, and 
distinguished between same-site and/or multi-focal PMD development.  
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Statistical Analyses 
Descriptive Statistics were used to summarise patient demography, clinico-
pathological features, clinical outcome and follow-up data. Pearson’s Chi-
squared tests (P values computed using Monte Carlo simulation with 2000 
replications) were used to assess the association between PMD clinico-
pathological features and post-treatment clinical outcome (disease free / 
persistent disease). All statistical analyses were carried out using the R 
Environment for Statistical Computing (version 3.2.5). 
 
Results 
Two distinct groups of treatment resistant PMD were identified: 34 patients 
who achieved disease free status following further intervention, and 53 who 
exhibited persistent PMD at study census despite treatment. All patients 
were noted to be tobacco smokers and regularly consumed alcohol. 
Disease Free Patients 
Data for the 34 disease free patients are listed in Table 1 which summarises 
individual patient ‘journeys’ from initial presentation to disease free status; 
there were 18 males and 16 females (age range 43-83yrs; mean 57.7yrs).  
Clinical Appearance. Presenting PMD appearance included 25 leukoplakias 
(74%), 8 erythroleukoplakias (23%) and 1 erythroplakia (3%). In 23 cases 
(68%), further PMD disease exhibited consistent clinical features, whilst 11 
(32%) changed appearance, in 8 (23%) initially presenting eryrtholeukoplakia 
transformed into a subsequent leukoplakia.  
Site. 16 lesions (47%) arose on the ventro-lateral tongue and floor of mouth, 
9 (26%) were seen on the buccal mucosa but other oral sites were less 
frequently involved. 15 further lesions (44%) arose specifically at the same-
site as their previous PMD, whilst 19 patients (56%) developed same and 
new-site (multi-focal) disease.  
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Histopathology. 28 initially presenting lesions (82%) were dysplastic on 
histopathological examination, with severe dysplasia or CiS seen in 15 
(44%); PVL was identified in 5 (15%), lichenoid inflammation in 5 (15%) and 
CHC in 2 (6%). 43 further PMD lesions were identified in this group over the 
study period: 13 patients (38%) exhibited the same histological features in 
both initial and further lesions, whilst 16 (47%) developed less severe and 5 
(15%) more severe pathological change, before ultimately reaching disease 
free status. 
Treatment. In total, 77 interventions were performed in the 34 patients: 61 
laser excisions (79%) and 16 (21%) ablative procedures. All patients 
underwent multiple interventions, with individual patient treatments ranging 
from 2 to 4 (mean 2.26). Time between first and last treatments varied 
between 4 and 129 months, with a mean of 33.1 months. 
Persistent Disease Patients 
Table 2 summarises the clinical course and disease outcome status for 53 
patients exhibiting persistent PMD disease: 31 males and 22 females (age 
range 24-93yrs; mean 61yrs).  
Clinical Appearance. 45 initial lesions appeared as leukoplakia (85%), 6 as 
erythroleukoplakia (11%) and 2 erythroplakia (4%); 45 (85%) retained 
consistent appearance whilst 8 (15%) changed appearance, with 5 (9%) 
erythroleukoplakic lesions transforming to leukoplakia.  
Site. Initial site involvement included 17 (32%) arising on ventro-lateral 
tongue and floor of mouth, 14 (26%) on buccal mucosa and 11 (21%) on 
gingiva / alveolar mucosa, with other sites involved less frequently. 28 
subsequent lesions (53%) were identified at the same site as presenting 
disease, whilst 25 (47%) exhibited same and new-site (multi-focal) lesions. 
Histopathology. 39 initial lesions (74%) exhibited dysplasia on biopsy, with 
29 mild or moderate dysplasia (55%) and only 12 (23%) showing severe 
dysplasia or CiS. PVL was initially seen in 20 cases (38%) and lichenoid 
inflammation in 9 (17%); no CHC cases were identified. Comparative 
histopathology data were only available for 17 cases undergoing further 
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biopsy: 5 (29%) showed similar pathological features with 7 (42%) less 
severe and 5 (29%) more severe than original biopsies. 
Treatment. 78 treatment interventions were recorded in this group, with 49 
excisions (63%) and 29 (37%) laser ablations. Only 15 patients underwent 
multiple interventions with the number per patient ranging between 1 and 4 
(mean 1.47); the time between first and final intervention for these cases 
ranged from 6 to 82 months (mean 35.53 months). 
Statistical Comparison 
Table 3 summarises statistical comparisons between disease free and 
persistent patient groups. No significant differences were seen for patient 
age and sex, nor for individual PMD lesion clinical appearance, site or 
histopathology diagnoses, including PVL or LI recognition. Statistical 
significance was identified, however, for a change in PMD appearance 
between initial and subsequent lesions (p=0.004) and for treatment 
intervention, both in terms of multiple versus single treatment (p=0.0005) and 
the use of excision rather than ablation techniques (p=0.027). 
 
Discussion 
The efficacy of interventional laser surgery, as both a diagnostic and 
treatment tool, has been well documented10. Recognition that 70% of ‘high-
risk’ PMD patients can achieve disease free status by intervention is 
unquestionably a treatment success4,8. It is, however, the subgroup of PMD 
patients who respond poorly to treatment that are likely to provide new and 
salient information regarding the nature of persistent and aggressive PMD 
disease4. 
Treatment resistance may be defined as PMD which persists or recurs, 
either at same or new-site origin, following interventional management. In the 
absence of relevant, prospective randomised trials, comparative studies of 
outcome in treated patient cohorts provide best contemporaneous evidence 
to detail PMD natural history and progression6,8. In view of the inability of 
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currently available biomarkers to rationalise clinical management decisions, 
in-depth study of observed patient outcomes may help validate clinico-
pathological predictors of PMD behaviour1,8.  
This paper attempted a detailed review of the natural history of 87 patients 
with treatment resistant PMD. Patients were identified from a previously 
reported cohort, which benefited from uniform diagnostic techniques, 
consistent treatment intervention and long-term observation of clinical 
outcome4,8. Accepting inevitable limitations of a single-centre, retrospective 
study, it was nonetheless possible to delineate two distinct types of treatment 
resistance: patients who ultimately achieved disease free status following 
further treatment and those with persistent PMD despite intervention.  
Clinico-Pathological Profiling 
Whilst the relatively small patient numbers in the analysis undoubtedly 
influenced statistical significance, it remains pertinent to characterise the 
clinico-pathological profiles of the two subgroups because such features may 
predict outcome and guide patient management decisions in the future.  
Disease free patients were slightly younger, often had lesions that changed 
appearance from erythroleukoplakia to ‘lower risk’ leukoplakia, developed 
further PMDs at new sites and, whilst often exhibiting quite severe dysplasia 
in presenting lesions, generally showed a reduction in severity in subsequent 
lesions.  
In contrast, the persistent disease cohort were generally older, more often 
male, frequently exhibited leukoplakia with PVL features at gingival and 
alveolar sites, and displayed less severe dysplasia in initial biopsies. Clinical 
appearance of lesions was more consistent between initial and further 
presentation, and same-site disease more prevalent. 
Diagnoses of PVL, with or without dysplasia, were made more frequently 
during later years of the study (2007 onwards), probably due to enhanced 
awareness amongst pathologists of the risks for persistent PMD disease and 
increased malignant transformation in PVL11. Although the identification of LI 
within PMD lesions has been linked to persistent and unfavourable disease 
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outcome12, no significant influence was seen on treatment resistance in this 
investigation.  
The Patient ‘Journey’ 
Active patient surveillance post-intervention is advised, not only to review 
treatment efficacy but also to effectively monitor patients for further disease, 
to recognise early signs of malignancy and to improve understanding of PMD 
natural history8,14. Table 1 details the cyclical nature of successful 
intervention for 34 disease free cases, passing from surgery to surveillance 
to repeat surgery on recognition of further disease, often taking several years 
and multiple treatments8,14; CO2 laser surgery has the advantage of 
facilitating repeat intervention without compromising oral form or function10,14. 
Despite consistent management decisions and repeated treatment, the 53 
patient ‘journeys’ summarized in Table 2 led to persistent disease outcomes.  
Treatment Intervention 
Whilst all PMD treatments were coordinated by the first author (PJT) and 
proceeded along well-established and consistent management 
guidelines4,8,10, it is clear that fewer interventions per patient were performed 
in the persistent disease group. Although many of these treatments 
comprised laser ablation of gingival and alveolar PVL, as previously 
advocated for this type of presentation8,12, repeat excision surgeries for more 
significant dysplastic lesions were also carried out, obviously with reduced 
efficacy compared to disease free cases.   
Whilst it is likely that individual management decisions and choice of 
treatment modality influence PMD clinical outcome15,16, it remains unclear 
from this retrospective study whether the inherent nature of the presenting 
PMD disease or the treatment intervention itself contributes the principal 
determinant of clinical outcome. Most probably, clinical outcome is the result 
of a complex interaction between ‘nature’ and ‘nurture’. 
It is, however, notable that repeat excision surgeries were performed much 
more frequently in patients achieving disease free status than those with 
persistent disease. Is the answer to PMD treatment resistance, therefore, 
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more treatment? Undoubtedly, future multi-centre, prospective investigations 
will be required to characterise this issue further. 
Clinical Relevance of Treatment Resistant PMD 
Despite recognising and defining salient clinico-pathological characteristics 
of treatment resistant PMD, an important question remains regarding the 
precise clinical relevance of persistent PMD. The hypothesis is clear: PMD 
treatment resistance reflects more aggressive disease and an enhanced 
cancer risk. Current evidence, however, is not wholly supportive of this 
concept, because none of the 87 treatment resistant patients in this analysis 
developed SCC. On the contrary, the majority of SCCs identified in the 590 
cohort were pre-existing and diagnosed unexpectedly upon initial PMD lesion 
excision4. 
Patient observational studies provide invaluable insight into the natural 
history of PMD, but it is evident that new approaches to clinico-pathological 
and biomolecular profiling are urgently needed to characterise disease 
progression in large population-based investigations. Only in this way will we 
truly enhance our knowledge and understanding of oral carcinogenesis and 
improve prognoses for patients.   
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TABLE 1: CLINICO-PATHOLOGICAL, TREATMENT AND CLINICAL OUTCOME 
DETAILS FOR DISEASE FREE PATIENTS (n=34) 
 
 
Patient 
No Sex Age 
 
 
Date Lesion Site 
Histopathology 
Diagnoses Treatment 
Site of 
Further PMD 
No of  
Interventions 
1 1997/6 M 47 Aug 
1997 
LK FOM CiS Excision     
    May 
2000 
LK FOM Severe Dysplasia Excision Same   2 
2 1998/12 M 60 Nov 
1998 
ELK Buccal Severe Dysplasia+LI Excision     
    Jun 
2005 
LK Buccal Mild Dysplasia Excision Same   2 
3 1999/9 M 53 May 
1999 
LK FOM CiS Excision     
    Jun 
2000 
LK FOM Severe Dysplasia Excision   
    Sept 
2001 
LK Lateral 
Tongue 
Severe Dysplasia Excision Same + New   3 
4 2001/5 F 58 Feb 
2001 
LK Buccal Moderate Dysplasia Excision   
    July 
2002 
LK Alveolus Moderate Dysplasia+LI Ablation New   2 
5 2001/12 M 60 Jun 
2001 
LK FOM Severe Dysplasia Excision     
    July 
2003 
LK Ventral 
Tongue 
Moderate Dysplasia Excision   
    Dec 
2004 
LK Lateral 
Tongue 
Moderate Dysplasia Excision New   3 
6 2002/9 F 64 Oct 
2002 
ELK FOM CiS Excision   
    July 
2004 
LK Fauces Severe Dysplasia Excision New   2 
7 2002/16 M 45 Dec 
2002 
LK Gingiva Mild Dysplasia Ablation   
    Sept 
2013 
LK Labial Mild Dysplasia Ablation New   2 
8 2004/18 F 55 July 
2004 
LK Palate Severe Dysplasia Ablation   
    Feb 
2005 
LK Fauces CiS Excision New   2   
9 2004/23 M 49 Oct 
2004 
LK Lateral 
Tongue 
CiS Excision   
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Patient 
No Sex Age 
 
 
Date Lesion Site 
Histopathology 
Diagnoses Treatment 
Site of 
Further PMD 
No of  
Interventions 
    Feb 
2005 
LK Lateral 
Tongue 
CiS Excision   
    Aug 
2012 
ELK Lateral 
Tongue 
Mild Dysplasia Excision New   3 
10 2006/6 M 83 Mar 
2006 
LK Lateral 
Tongue 
Severe Dysplasia Excision     
    Jun 
2007 
LK Ventral 
Tongue 
Moderate Dysplasia Excision New   2 
11 2006/7 F 67 Jun 
2006 
LK Lateral 
Tongue 
Moderate Dysplasia Excision   
    Sept 
2007 
LK Lateral 
Tongue 
Mild Dysplasia Excision Same   2 
12 2007/26 F 61 Nov 
2007 
LK Buccal Severe Dysplasia Excision   
    Mar 
2011 
ELK Alveolus HK + LI Ablation   
    Mar 
2012 
EK Alveolus Moderate Dysplasia Ablation Same + New   3 
13 2008/3 M 43 Feb 
2008 
ELK FOM Mild Dysplasia Excision     
    June 
2014 
LK FOM Mild Dysplasia Ablation Same   2 
14 2009/14 M 48 Mar 
2009 
LK Ventral 
Tongue 
Severe Dysplasia Excision     
    Apr 
2010 
LK FOM Severe Dysplasia+LI Excision New   2 
15 2009/23 F 44 Jul 
2009 
ELK Dorsum 
Tongue 
CHC Excision     
    Jun 
2014 
LK Dorsum 
Tongue 
CHC Excision Same   2 
16 2009/33 F 63 Oct 
2009 
ELK Lateral 
Tongue 
Severe Dysplasia  Excision     
    Oct 
2011 
ELK Lateral 
Tongue 
Severe Dysplasia Ablation   
    July 
2012 
LK Ventral 
Tongue 
Mild Dysplasia Ablation Same + New   3 
17 2009/40 M 68 Nov 
2009 
ELK FOM CiS Excision    
    July 
2011 
LK FOM CiS Ablation   
    May 
2013 
LK FOM Severe Dysplasia Excision   
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Patient 
No Sex Age 
 
 
Date Lesion Site 
Histopathology 
Diagnoses Treatment 
Site of 
Further PMD 
No of  
Interventions 
    Sept 
2014 
LK Ventral 
Tongue 
Severe Dysplasia Excision Same + New   4 
18 2010/10 M 58 Mar 
2010 
LK Buccal PVL Excision     
    Oct 
2010 
LK Labial 
Comm 
PVL Excision New   2 
19 2011/3 M 57 Jan 
2011 
LK Palate Moderate Dysplasia+LI Excision   
    May 
2012 
LK Palate Moderate Dysplasia Excision Same   2 
20 2011/9 F 77 Feb 
2011 
LK Buccal Mild Dysplasia PVL Excision   
    Jun 
2013 
LK Buccal Mild Dysplasia+LI Excision Same   2 
21 2011/17 F 72 Mar 
2011 
LK FOM Mild Dysplasia PVL Excision   
    Jun 
2013 
LK Buccal Mild Dysplasia+LI Excision New   2 
22 2011/24 M 65 May 
2011 
LK Palate Severe Dysplasia Excision   
    Nov 
2012 
LK Lateral 
Tongue 
Moderate Dysplasia Excision   
    Nov 
2014 
ELK RM Severe Dysplasia Excision New   3 
23 2011/27 F 45 May 
2011 
LK Palate Mild Dysplasia Excision   
    Mar 
2014 
LK Palate Mild Dysplasia Ablation Same   2 
24 2011/34 M 47 Jun 
2011 
LK Labial 
Comm 
CHC Excision   
    Jun 
2013 
LK Labial 
Comm 
CHC Ablation Same   2 
25 2011/50 M 74 Sept 
2011 
LK Lateral 
Tongue 
Mild Dysplasia PVL Excision   
    July 
2012 
LK Buccal Mild Dysplasia Excision New   2 
26 2011/51 M 46 Sept 
2011 
ELK Labial 
Comm 
Mild Dysplasia PVL Excision     
    Dec 
2013 
LK Ventral 
Tongue 
Severe Dysplasia Excision   
    Dec 
2014 
LK Labial 
Comm 
Mild Dysplasia PVL Ablation Same + New  3 
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Patient 
No Sex Age 
 
 
Date Lesion Site 
Histopathology 
Diagnoses Treatment 
Site of 
Further PMD 
No of  
Interventions 
27 2011/62 F 57 Dec  
2011 
LK Gingiva HK + LI Ablation   
    Jun 
2014 
LK Gingiva HK + LI Ablation Same   2 
28 2012/24 F 51 Jun 
2012 
LK Buccal PVL Excision     
    May 
2013 
LK Buccal Mild Dysplasia PVL Excision Same   2 
29 2013/1 M 70 Jan 
2013 
ELK Buccal Mild Dysplasia+LI Excision   
    May 
2013 
ELK Buccal HK + LI Excision Same   2 
30 2013/5 M 54 Jan 
2013 
EK Fauces Severe Dysplasia Excision   
    Feb 
2014 
LK Fauces Severe Dysplasia Excision Same   2 
31 2013/30 F 60 May 
2013 
LK Alveolus HK + LI Ablation     
    Jun 
2014 
LK FOM Mild Dysplasia Excision New   2 
32 2013/34 M 47 May 
2013 
LK FOM Mild Dysplasia Excision   
    May 
2014 
LK FOM Mild Dysplasia Excision Same   2 
33 2013/42 F 52 Jun 
2013 
LK Lateral 
Tongue 
Severe Dysplasia  Excision   
    May 
2014 
LK Lateral 
Tongue 
Severe Dysplasia Excision Same   2 
34 2013/54 F 63 Aug 
2013 
LK FOM Mild Dysplasia Excision   
    Jun 
2014 
LK Palate Mild Dysplasia Excision New   2  
 
LK: leukoplakia; ELK: erythroleukoplakia; EK: erythroplakia; Labial Comm: Labial 
Commissure; FOM: floor of mouth; RM: retromolar region; PVL: proliferative verrucous 
leukoplakia; HK: hyperkeratosis; LI: lichenoid inflammation; CHC: chronic hyperplastic 
candidosis; CiS: carcinoma-in-situ 
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TABLE 2: CLINICO-PATHOLOGICAL, TREATMENT AND CLINICAL OUTCOME DETAILS FOR 
PERSISTENT DISEASE PATIENTS (n=53) 
 
 
Patient 
No Sex Age 
 
 
Date Lesion Site 
Histopathology 
Diagnoses Treatment 
Site of 
Persistent 
PMD 
No of  
Interventions 
Clinical 
Outcome 
1 2000/12 F 54 March 
2000 
LK Alveolus Moderate Dysplasia+LI Ablation Same + New   1 MF LK 
2 2000/33 M 59 Oct 
2000 
LK Ventral 
Tongue 
Moderate Dysplasia Excision      
    Nov 
2006 
LK Ventral 
Tongue 
Mild Dysplasia Excision Same   2 Ventral 
Tongue LK 
3 2001/13 M 55 July 
2001 
ELK Fauces CiS Excision Same + New   1 MF LK 
4 2001/16 F 65 Sept 
2001 
LK Gingiva Mild Dysplasia Ablation Same   1 Gingiva LK 
5 2002/8 M 41 June 
2002 
LK FOM CiS Excision    
    June 
2004 
ELK FOM Moderate Dysplasia Ablation    
    May 
2005 
LK Ventral 
Tongue 
Severe Dysplasia Excision    
    May 
2007 
ELK Lateral 
Tongue 
Severe Dysplasia Excision New   4 MF ELK 
6 2002/10 M 27 Oct 
2002 
LK FOM Moderate Dysplasia+LI Excision Same   1 FOM LK 
7 2003/6 F 67 Apr 
2003 
EK Buccal Severe Dysplasia Excision      
    Feb 
2010 
EK Lateral 
Tongue 
Severe Dysplasia Excision New   2 MF ELK 
8 2005/2 M 69 Jan 
2005 
LK FOM Moderate Dysplasia Excision Same   1 FOM LK 
9 2005/4 M 55 Feb 
2005 
LK Lateral 
Tongue 
CiS Excision    
    Mar 
2006 
LK FOM Mild Dysplasia Observation New   1 FOM LK 
10 2006/11 M 56 Aug 
2006 
LK FOM Severe Dysplasia Excision      
    Oct 
2010 
ELK FOM Severe Dysplasia Excision Same   2 FOM ELK 
11 2006/17 F 93 Nov 
2006 
EK Buccal Severe Dysplasia Excision Same   1 MF LK 
12 2007/7 F 58 Mar 
2007 
LK FOM Mild Dysplasia Ablation      
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No Sex Age 
 
 
Date Lesion Site 
Histopathology 
Diagnoses Treatment 
Site of 
Persistent 
PMD 
No of  
Interventions 
Clinical 
Outcome 
    Mar 
2009 
LK Alveolus Mild Dysplasia Ablation    
    Oct 
2014 
LK Buccal Mild Dysplasia PVL Ablation New   3 MF LK 
13 2008/11 M 56 Mar 
2008 
LK Lateral 
Tongue 
Severe Dysplasia Excision      
    Mar 
2009 
LK Lateral 
Tongue 
Moderate Dysplasia Excision Same   2 Lateral 
Tongue LK 
14 2008/28 F 67 Sept 
2008 
LK Palate Mild Dysp Excision      
    Feb 
2010 
LK Buccal HK + LI Excision    
    Oct 
2012 
LK Alveolus Mild Dysplasia PVL Ablation New   3 MF LK 
15 2009/10 M 52 Feb 
2009 
LK Labial 
Comm 
Mild Dysplasia Excision Same   1 Labial 
Comm LK 
16 2010/6 M 69 Mar 
2010 
LK FOM Mild Dysplasia PVL Excision New   1 Buccal LK 
17 2010/8 M 67 Mar 
2010 
ELK Lateral 
Tongue 
Mild Dysplasia+LI Excision Same   1 Lateral 
Tongue 
ELK 
18 2010/19 M 72 June 
2010 
LK Alveolus PVL Excision New   1 MF LK 
19 2010/28 F 56 Sept 
2010 
ELK Labial 
Comm 
Moderate Dysplasia Excision New   1 MF LK 
20 2010/30 M 70 Sept 
2010 
LK Buccal Moderate Dysplasia 
PVL 
Excision      
    Sept 
2011 
LK RM Moderate Dysplasia Ablation New   2 MF LK 
21 2010/34 F 59 Oct 
2010 
LK Palate HK Ablation Same   1 Palate LK 
22 2010/39 M 79 Dec 
2010 
LK Alveolus Mild Dysplasia PVL Excision      
    Oct 
2013 
LK Palate PVL Ablation    
    Oct 
2014 
LK Alveolus Mild Dysplasia PVL Ablation New   3 MF LK 
23 2011/1 M 63 Jan 
2011 
LK Labial Severe Dysplasia+LI Ablation Same   1 Labial ELK 
24 2011/11 F 61 Feb 
2011 
LK Fauces Moderate Dysplasia 
PVL 
Excision New   1 MF LK 
25 2011/12 F 70 Feb 
2011 
LK Buccal Moderate Dysplasia 
PVL 
Excision New   1 MF LK 
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No of  
Interventions 
Clinical 
Outcome 
26 2011/22 M 42 Mar 
2011 
LK Labial Mild Dysplasia Ablation      
    Nov 
2012 
LK Labial Mild Dysplasia Ablation Same   2 Labial LK 
27 2011/38 M 38 July  
2011 
LK Buccal Mild Dysplasia PVL Excision Same   1 Buccal LK 
28 2011/48 F 56 Sept 
2011 
ELK Lateral 
Tongue 
Moderate Dysplasia Excision      
    May 
2012 
ELK Buccal Mild Dysplasia+LI Excision    
    June 
2014 
LK Lateral 
Tongue 
Mild Dysplasia+LI Excision New   3 Lateral 
Tongue LK 
29 2011/49 M 55 Sept 
2011 
LK Labial Mild Dysplasia PVL Excision New   1 MF LK 
30 2011/58 F 58 Nov 
2011 
LK Gingiva Mild Dysplasia PVL Ablation Same   1 Gingiva LK 
31 2011/60 M 49 Dec 
2011 
ELK Labial 
Comm 
Mild Dysplasia PVL Excision      
    Mar 
2013 
LK Labial 
Comm 
PVL Ablation    
    July 
2013 
LK Ventral 
Tongue 
Moderate Dysplasia+LI Excision New   3 Labial 
Comm LK 
32 2011/61 M 68 Dec 
2011 
LK Alveolus Mild Dysplasia Ablation Same   1 Alveolus 
LK 
33 2012/2 F 62 Jan 
2012 
LK FOM Moderate Dysplasia 
PVL 
Excision      
    Jan 
2013 
LK FOM Mild Dysplasia PVL Ablation    
    May 
2013 
LK FOM Mild Dysplasia PVL Ablation Same   3 FOM LK 
34 2012/3 M 51 Jan 
2012 
LK Buccal HK + LI Excision Same   1 Buccal LK 
35 2012/5 M 80 Jan 
2012 
LK Buccal Moderate Dysplasia Ablation New   1 MF LK 
36 2012/15 F 24 Apr 
2012 
LK FOM Mild Dysplasia+LI Excision   Same   1 FOM LK 
37 2012/18 F 57 May 
2012 
LK Dorsum 
Tongue 
Mild Dysplasia PVL Excision Same + New   1 MF LK 
38 2012/20 F 56 May 
2012 
ELK Lateral 
Tongue 
Severe Dysplasia Excision Same   1 Lateral 
Tongue LK 
39 2012/39 M 64 Aug 
2012 
LK Gingiva PVL Excision New   1 MF LK 
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Interventions 
Clinical 
Outcome 
40 2012/40 M 58 Sept 
2012 
LK Ventral 
Tongue 
Moderate Dysplasia Excision Same + New   1 MF LK 
41 2012/41 F 71 Oct 
2012 
LK Buccal Mild Dysplasia PVL Ablation New   1 MF LK 
42 2012/48 M 59 Dec 
2012 
LK Ventral 
Tongue 
Severe Dysplasia Excision Same   1 Ventral 
Tongue LK 
43 2013/3 F 83 Jan 
2013 
LK Buccal HK + LI Excision Same + New   1 MF LK 
44 2013/6 M 56 Jan 
2013 
LK Labial PVL Ablation Same + New   1 MF LK 
45 2013/15 M 75 Mar 
2013 
LK Gingiva PVL Ablation      
    Feb 
2014 
LK Gingiva Mild Dysplasia PVL Ablation Same   2 Gingiva LK 
46 2013/19 F 63 Mar 
2013 
LK Alveolus HK + LI Ablation Same   1 Alveolus 
LK 
47 2013/47 M 68 Jun 
2013 
LK Alveolus PVL Excision Same   1 Alveolus 
LK 
48 2013/69 M 82 Oct 
2013 
LK Palate PVL Ablation      
    Oct 
2014 
LK Alveolus Mild Dysplasia PVL Ablation Same + New     2 MF LK 
49 2013/71 M 59 Nov 
2013 
LK Lateral 
Tongue 
Moderate Dysplasia+LI Excision Same + New   1 MF LK 
50 2013/72 F 73 Dec 
2013 
LK Labial Severe Dysplasia Excision Same   1 Labial LK 
51 2014/14 F 53 May 
2014 
LK FOM Mild Dysplasia PVL Excision      
    Nov 
2014 
LK Gingiva Mild Dysplasia PVL Ablation New    2 MF LK 
52 2014/19 F 65 June 
2014 
LK Gingiva PVL Ablation Same   1 Gingiva LK 
53 2014/25 M 63 Sept 
2014 
LK Buccal Severe Dysplasia Excision Same + New   1 MF LK 
 
LK: leukoplakia; ELK: erythroleukoplakia; EK: erythroplakia; Labial Comm: Labial Commissure; FOM: 
floor of mouth; RM: retromolar region; MF: multi-focal; PVL: proliferative verrucous leukoplakia; HK: 
hyperkeratosis; LI: lichenoid inflammation; CHC: chronic hyperplastic candidosis; CiS: carcinoma-in-
situ 
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TABLE 3:  STATISTICAL COMPARISON OF CLINICO-PATHOLOGICAL FEATURES BETWEEN 
DISEASE FREE AND PERSISTENT DISEASE PATIENT GROUPS 
(Pearson Chi-Square Testing) 
 
 
       𝝌𝟐    p-value 
Age 1.293 p=0.28 
Sex 0.259 p=0.67 
Initial Lesion Appearance 2.293 p=0.35 
Initial Lesion Site 7.659 p=0.36 
Initial Histopathology Diagnosis 5.816 p=0.12 
PVL in Initial Lesion 3.949 p=0.09 
Lichenoid Inflammation in Initial Lesion 0.021 p=1.0 
Treatment Intervention (Single vs Multiple) 43.282 p=0.0005* 
Treatment Intervention (Excision vs Ablation) 5.058 p=0.027* 
Time (months) between Initial and Final Intervention 0.157 p=0.76 
Change in Lesion Appearance 8.971 p=0.004* 
Change in Lesion Site (Same vs Multi-Focal) 0.077 p=0.83 
Change in Histopathology Diagnosis 1.587 p=0.51 
  
*Statistical Significance at α=0.05 
